Macrophages as Active Nanocarriers for Targeted Early and Adjuvant Cancer Chemotherapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Solid tumors often exhibit the enhanced permeability and retention (EPR) effect, enabling passive targeting of nanomedicines.
• However, early-stage or post-surgery tumors frequently lack pathological EPR features, termed EPR-deficient, limiting nanomedicine efficacy.
• Macrophages possess inherent tumor-homing capabilities, vascular extravasation, and stealth properties, making them potential drug carriers.

Purpose of the Study:

• To explore the potential of macrophages as carriers for nanomedicines to overcome EPR-deficient tumor limitations.
• To summarize critical considerations, progress, challenges, and future prospects of macrophage-based nanomedicine delivery.
• To enable rational design of EPR-independent nanomedicines for targeted early and adjuvant cancer chemotherapy.

Main Methods:

• Review and synthesis of current research on macrophages as drug delivery vehicles.
• Analysis of macrophage properties relevant to tumor penetration and drug loading (phagocytosis, migration).
• Discussion of strategies for loading nanomedicines into macrophages and their therapeutic implications.

Main Results:

• Macrophages can actively target tumors independent of the EPR effect, addressing limitations in EPR-deficient cancers.
• Macrophage-loaded nanomedicines combine active tumor homing with the benefits of nanocarriers.
• This strategy offers a viable approach for targeted delivery in early-stage and residual disease settings.

Conclusions:

• Macrophages represent a promising cell-based platform for delivering nanomedicines to EPR-deficient tumors.
• Further research into rational design is crucial for optimizing macrophage-mediated nanomedicine delivery for cancer therapy.
• This approach holds potential for enhancing targeted early and adjuvant cancer chemotherapy.